T Cell Mediated Conversion of a Non-Anti-La Reactive B Cell to an Autoreactive Anti-La B Cell by Somatic Hypermutation.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
26 Jan 2021
Historique:
received: 29 12 2020
revised: 20 01 2021
accepted: 22 01 2021
entrez: 3 2 2021
pubmed: 4 2 2021
medline: 14 4 2021
Statut: epublish

Résumé

Since the first description of nuclear autoantigens in the late 1960s and early 1970s, researchers, including ourselves, have found it difficult to establish monoclonal antibodies (mabs) against nuclear antigens, including the La/SS-B (Sjögrens' syndrome associated antigen B) autoantigen. To date, only a few anti-La mabs have been derived by conventional hybridoma technology; however, those anti-La mabs were not bona fide autoantibodies as they recognize either human La specific, cryptic, or post-translationally modified epitopes which are not accessible on native mouse La protein. Herein, we present a series of novel murine anti-La mabs including truly autoreactive ones. These mabs were elicited from a human La transgenic animal through adoptive transfer of T cells from non-transgenic mice immunized with human La antigen. Detailed epitope and paratope analyses experimentally confirm the hypothesis that somatic hypermutations that occur during T cell dependent maturation can lead to autoreactivity to the nuclear La/SS-B autoantigen.

Identifiants

pubmed: 33530489
pii: ijms22031198
doi: 10.3390/ijms22031198
pmc: PMC7865296
pii:
doi:

Substances chimiques

Autoantibodies 0
Autoantigens 0
Epitopes 0
Ribonucleoproteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : GM63497
Pays : United States
Organisme : Oklahoma Center for the Advancement of Science and Technology OK, USA
ID : HR01-003

Références

Free Radic Biol Med. 2006 Aug 15;41(4):549-56
pubmed: 16863987
J Immunol. 2001 May 1;166(9):5826-34
pubmed: 11313427
J Exp Med. 2010 Sep 27;207(10):2225-37
pubmed: 20805563
J Autoimmun. 2018 Jun;90:116-131
pubmed: 29503042
Nat Struct Mol Biol. 2004 Apr;11(4):323-9
pubmed: 15004549
J Exp Med. 1987 Dec 1;166(6):1627-40
pubmed: 2445893
Immunogenetics. 1999 Sep;49(10):829-34
pubmed: 10436175
J Biol Chem. 1997 May 2;272(18):12076-82
pubmed: 9115276
J Autoimmun. 2013 May;42:105-16
pubmed: 23352111
J Autoimmun. 1992 Dec;5(6):771-85
pubmed: 1489488
Adv Immunol. 1989;44:93-151
pubmed: 2646863
Clin Exp Immunol. 1995 Jul;101(1):45-54
pubmed: 7621591
Am J Med. 1991 Mar;90(3):283-5
pubmed: 1848393
J Exp Med. 1995 Feb 1;181(2):453-61
pubmed: 7530756
Immunology. 2002 Jul;106(3):336-42
pubmed: 12100721
Blood Cancer J. 2018 Aug 22;8(9):81
pubmed: 30190468
J Autoimmun. 1990 Dec;3(6):701-13
pubmed: 1708260
J Clin Invest. 1985 Aug;76(2):801-6
pubmed: 2411763
Sci Rep. 2020 Feb 7;10(1):2141
pubmed: 32034289
Hum Antibodies Hybridomas. 1992 Apr;3(2):75-80
pubmed: 1633268
Clin Exp Immunol. 2006 Feb;143(2):237-48
pubmed: 16412047
J Immunol. 1986 May 15;136(10):3744-9
pubmed: 2422260
J Immunol. 2006 Aug 1;177(3):1698-707
pubmed: 16849479
Biochim Biophys Acta. 1997 Mar 27;1356(1):53-63
pubmed: 9099991
Cancer Immunol Immunother. 2019 Oct;68(10):1713-1719
pubmed: 31542798
J Immunol Methods. 1985 Feb 28;77(1):63-76
pubmed: 3882844
Oncoimmunology. 2020 Jul 3;9(1):1785608
pubmed: 32923149
J Autoimmun. 1995 Dec;8(6):825-42
pubmed: 8824709
Rheum Dis Clin North Am. 2000 May;26(2):215-27, v
pubmed: 10768210
Discov Med. 2013 Feb;15(81):85-92
pubmed: 23449110
J Immunol. 1986 Nov 15;137(10):3162-8
pubmed: 3021847
Methods Mol Biol. 2019;1855:87-91
pubmed: 30426409
Onco Targets Ther. 2020 Jun 12;13:5515-5527
pubmed: 32606767
Oncoimmunology. 2020 Apr 5;9(1):1743036
pubmed: 32426176
Arthritis Rheum. 1986 Feb;29(2):196-206
pubmed: 3485431
Structure. 2003 Jul;11(7):833-43
pubmed: 12842046
Immunol Lett. 2019 Jul;211:13-22
pubmed: 31091431
J Exp Clin Cancer Res. 2020 May 5;39(1):77
pubmed: 32370811
Cell. 1987 Sep 11;50(6):819-20
pubmed: 3621346
Cancers (Basel). 2020 May 21;12(5):
pubmed: 32455621
Oncotarget. 2017 May 9;8(19):31368-31385
pubmed: 28404896
Oncoimmunology. 2017 Feb 6;6(4):e1287246
pubmed: 28507794
J Autoimmun. 2011 Sep;37(2):104-12
pubmed: 21632208
Cancer Immunol Immunother. 2019 Sep;68(9):1401-1415
pubmed: 31414180
Oncotarget. 2017 Dec 21;9(7):7487-7500
pubmed: 29484126
Blood Cancer J. 2016 Aug 12;6(8):e458
pubmed: 27518241
J Rheumatol Suppl. 1992 Jan;32:18-24
pubmed: 1319486
Eur J Biochem. 1995 Sep 1;232(2):611-9
pubmed: 7556214
PLoS One. 2014 Apr 03;9(4):e93745
pubmed: 24699869
Proc Natl Acad Sci U S A. 1986 Oct;83(20):7770-4
pubmed: 2429318
J Exp Med. 1970 Aug 1;132(2):211-50
pubmed: 5508247
Sci Rep. 2019 Jul 22;9(1):10547
pubmed: 31332252
Ann Rheum Dis. 2000 Apr;59(4):243-51
pubmed: 10733469
Cell. 1990 Jan 12;60(1):85-93
pubmed: 1688513
Arthritis Rheum. 1997 Nov;40(11):1917-27
pubmed: 9365079
J Am Coll Cardiol. 1998 Jun;31(7):1658-66
pubmed: 9626848
PLoS One. 2011 Jan 21;6(1):e16315
pubmed: 21283706
J Labelled Comp Radiopharm. 2019 Jun 30;62(8):533-540
pubmed: 30889625
Oncoimmunology. 2019 Sep 7;8(11):1659095
pubmed: 31646084
Exp Cell Res. 1997 Aug 1;234(2):329-35
pubmed: 9260901

Auteurs

Michael P Bachmann (MP)

Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 03128 Dresden, Germany.
University Cancer Center (UCC), Tumor Immunology, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, 01307 Dresden, Germany.
National Center for Tumor Diseases (NCT), 01307 Dresden, Germany.
German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Tabea Bartsch (T)

Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 03128 Dresden, Germany.

Claudia C Bippes (CC)

Institute of Immunology, Medical Faculty Carl Gustav Carus Dresden, Technical University Dresden, 01307 Dresden, Germany.

Dominik Bachmann (D)

University Cancer Center (UCC), Tumor Immunology, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, 01307 Dresden, Germany.

Edinson Puentes-Cala (E)

Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 03128 Dresden, Germany.
Corporación para la Investigación de la Corrosión (CIC), Piedecuesta, Santander 681011, Colombia.

Jennifer Bachmann (J)

University Cancer Center (UCC), Tumor Immunology, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, 01307 Dresden, Germany.

Holger Bartsch (H)

Institute of Immunology, Medical Faculty Carl Gustav Carus Dresden, Technical University Dresden, 01307 Dresden, Germany.

Claudia Arndt (C)

Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 03128 Dresden, Germany.

Stefanie Koristka (S)

Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 03128 Dresden, Germany.

Liliana R Loureiro (LR)

Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 03128 Dresden, Germany.

Alexandra Kegler (A)

Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 03128 Dresden, Germany.

Markus Laube (M)

Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 03128 Dresden, Germany.

Joanne K Gross (JK)

The Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Tim Gross (T)

The Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Biji T Kurien (BT)

The Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

R Hal Scofield (RH)

The Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

A Darise Farris (AD)

The Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Judith A James (JA)

The Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Marc Schmitz (M)

National Center for Tumor Diseases (NCT), 01307 Dresden, Germany.
German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Institute of Immunology, Medical Faculty Carl Gustav Carus Dresden, Technical University Dresden, 01307 Dresden, Germany.

Anja Feldmann (A)

Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 03128 Dresden, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH